Oral Oncology Reports最新文献_第9页

Optimizing 3D printing prosthesis technology for rehabilitation of oral cancer patients 优化用于口腔癌患者康复的 3D 打印假体技术

Oral Oncology Reports Pub Date : 2024-09-25 DOI: 10.1016/j.oor.2024.100661

N. Gopi Chander, Lakshita Sharma, Amrutha Manoj Kumar, Lakshmi Raj

{"title":"Optimizing 3D printing prosthesis technology for rehabilitation of oral cancer patients","authors":"N. Gopi Chander, Lakshita Sharma, Amrutha Manoj Kumar, Lakshmi Raj","doi":"10.1016/j.oor.2024.100661","DOIUrl":"10.1016/j.oor.2024.100661","url":null,"abstract":"<div><div>Oral cancer patients face significant challenges in prosthetic rehabilitation due to tissue loss from surgical interventions and the lasting side effects of treatments such as radiation therapy. Traditional methods of prosthesis fabrication often struggle to account for the anatomical changes caused by cancer treatments, leading to functional and aesthetic limitations. 3D printing technology, with its ability to produce customized, patient-specific prostheses, presents a promising solution for overcoming these challenges. By employing advanced imaging techniques like CT and MRI, 3D printing allows for the precise modeling of the oral cavity, improving the fit, comfort, and functionality of prostheses.</div><div>In addition to enhancing the accuracy of prosthesis design, 3D printing plays a crucial role in surgical reconstruction by enabling surgeons to plan more precise interventions. This reduces the need for multiple surgeries and improves recovery time. The integration of 3D printing with oncologic care, including collaboration between surgical teams and oncologists, further streamlines treatment and enhances patient outcomes. Despite these advantages, limitations remain, particularly regarding the durability and biocompatibility of 3D printing materials. Future advancements, including bioprinting and the development of smart materials, hold the potential to further revolutionize prosthetic rehabilitation for oral cancer patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100661"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142359076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sebaceous adenoma of the parotid gland encasing the facial nerve: Case report and review of the literature 包裹面神经的腮腺皮脂腺瘤：病例报告和文献综述

Oral Oncology Reports Pub Date : 2024-09-25 DOI: 10.1016/j.oor.2024.100663

Bhavik Singh , Kelly R. Magliocca , David Chou , Jennifer H. Gross , Jennifer L. Becker , Nicole C. Schmitt

{"title":"Sebaceous adenoma of the parotid gland encasing the facial nerve: Case report and review of the literature","authors":"Bhavik Singh , Kelly R. Magliocca , David Chou , Jennifer H. Gross , Jennifer L. Becker , Nicole C. Schmitt","doi":"10.1016/j.oor.2024.100663","DOIUrl":"10.1016/j.oor.2024.100663","url":null,"abstract":"<div><h3>Background</h3><div>Sebaceous adenoma of the salivary glands are uncommon benign neoplasms, comprising about 0.1 % of salivary tumors. These tumors can be difficult to recognize with heterogeneous appearance on imaging.</div></div><div><h3>Case report</h3><div>A 67-year-old man presented with a painless, progressively growing left parotid mass. Imaging showed a heterogenous, partially cystic mass in the superficial and deep lobes of the parotid with some areas of adipose density. Intraoperatively, a mass with sebaceous differentiation was found to be encasing the main trunk and pes anserinus of the facial nerve, requiring nerve sacrifice for en bloc resection. Final pathology revealed a sebaceous adenoma with intense xanthomatous reaction compressing the facial nerve.</div></div><div><h3>Conclusion</h3><div>Although benign and associated with little risk of recurrence, sebaceous adenomas may be difficult to recognize on preoperative workup and may be locally aggressive. Complete surgical resection is the mainstay of therapy, but rehabilitation may be required in the event of facial nerve involvement.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100663"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142327036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trismus following facial nerve sacrifice and reanimation surgery: Incidence and management 面神经牺牲和再植手术后的三联症：发生率和处理

Oral Oncology Reports Pub Date : 2024-09-21 DOI: 10.1016/j.oor.2024.100658

Lachlan Jackson , Emma Charters , Masako Dunn , Jonathan Clark , Tsu-Hui (Hubert) Low

引用次数: 0

Sex & marital differences in delayed pharyngeal cancer treatment before and after medicaid expansion 医疗补助扩展前后咽癌延迟治疗的性别和婚姻差异

Oral Oncology Reports Pub Date : 2024-09-19 DOI: 10.1016/j.oor.2024.100653

Jason Semprini

{"title":"Sex & marital differences in delayed pharyngeal cancer treatment before and after medicaid expansion","authors":"Jason Semprini","doi":"10.1016/j.oor.2024.100653","DOIUrl":"10.1016/j.oor.2024.100653","url":null,"abstract":"<div><h3>Objective</h3><p>In the United States, pharyngeal cancer has become the most common type of head and neck cancer, with 80 % of cases found in males. Although disparities in treatment delays have been observed in pharyngeal patients, less is known about how policies facilitate timely care. This study aimed to estimate the association between Medicaid expansion and delaying initiation of pharyngeal cancer treatment.</p></div><div><h3>Methodology</h3><p>We extracted Surveillance, Epidemiological, End Results (SEER) case data to analyze pharyngeal cancers diagnosed between 2000 and 2018. The outcome of interest was a binary variable indicating if the patient initiated treatment two or more months after diagnosis. We conducted subgroup analyses by sex, marital status, and type of treatment received (surgery, radiation, chemotherapy, post-operative radiation, systemic therapy). We implemented the Matrix Completion algorithm to account for staggered rollout of Medicaid expansion within our difference-in-differences design.</p></div><div><h3>Results</h3><p>Our sample included 79,433 patients diagnosed with pharynx cancer. Delayed treatment was lowest among married females receiving systemic therapy (5 %), and highest among married males and females not recommended to receive surgery (43 %). Generally, there was no association between Medicaid expansion and changes in delayed treatment. Subgroup analyses show that Medicaid expansion was associated with reduced treatment delays in unmarried females receiving systemic therapy (−4.5%-points), and married males receiving chemotherapy (Est. = −2.6%-points), radiotherapy (Est. = −3.1%-points), and married males not recommended to receive surgery (Est. = −4.6%-points).</p></div><div><h3>Conclusions</h3><p>Given the importance of timely pharyngeal cancer treatment, health systems must identify and address the drivers of treatment delays to advance cancer equity.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100653"},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004990/pdfft?md5=664276d5ddc4f7bf3248c61ca505846e&pid=1-s2.0-S2772906024004990-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of flap complications following pectoralis major myocutaneous flap reconstruction for oral cancers 评估胸大肌皮瓣重建治疗口腔癌后的皮瓣并发症

Oral Oncology Reports Pub Date : 2024-09-19 DOI: 10.1016/j.oor.2024.100655

Nadimul Hoda , Aastha Moza , Ankita Saraf , Sravani Bhogaraju , Irfan Ahmed

{"title":"Evaluation of flap complications following pectoralis major myocutaneous flap reconstruction for oral cancers","authors":"Nadimul Hoda , Aastha Moza , Ankita Saraf , Sravani Bhogaraju , Irfan Ahmed","doi":"10.1016/j.oor.2024.100655","DOIUrl":"10.1016/j.oor.2024.100655","url":null,"abstract":"<div><h3>Background</h3><div>Oral cavity cancer is among the leading cause of cancer death in India. Pectoralis major myocutaneous flaps (PMMC) are still widely used for the reconstruction of defects pertaining to head and neck region, though free flaps are considered to be gold standard. The study was aimed to identify the risk factors involved in post - operative complications of PMMC Flap for oral subsites.</div></div><div><h3>Methods</h3><div>A total of 266 patients operated in an oncology institute over 2 years of time was evaluated based on their demographic data, pre and post-surgery details, post-operative flap morbidity were collected retrospectively from master case sheets from January 2022 to January 2024. Factors such as age, gender, stage of disease, diabetic status, and hypoprotenemia and radiation therapy were seen, analysed to find their relation in causing flap complications.</div></div><div><h3>Results</h3><div>Totally 266 patients were included for analysis and 16.9 % had major flap complications. On detailed analysis, it was seen that larger bipaddled flaps had higher flap complication rate, highest being wound infection.</div></div><div><h3>Conclusion</h3><div>PMMC Flap is a viable option for head and neck cancer reconstruction, specifically in cases where free microvascular flaps are not done routinely and patient presents with multiple comorbidities. Careful patient selection, pre – operative optimization, operating surgeon experience and post-operative care are contributing factors to reduce flap complications.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100655"},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142359075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiant advances: The future of brachytherapy in oral oncology 辐射进步：口腔肿瘤近距离放射治疗的未来

Oral Oncology Reports Pub Date : 2024-09-19 DOI: 10.1016/j.oor.2024.100654

Shyamaladevi Babu, Madhan Krishnan

{"title":"Radiant advances: The future of brachytherapy in oral oncology","authors":"Shyamaladevi Babu, Madhan Krishnan","doi":"10.1016/j.oor.2024.100654","DOIUrl":"10.1016/j.oor.2024.100654","url":null,"abstract":"<div><div>Brachytherapy has become integral to the treatment of oral cancers, offering the advantage of delivering high doses of radiation directly to tumors while minimizing exposure to surrounding healthy tissues. This review examines recent advancements that have significantly improved the precision and effectiveness of brachytherapy. The integration of high-resolution imaging technologies, such as MRI and CT scans, has enhanced tumor delineation, enabling more accurate placement of radioactive sources. Innovations in radioactive sources, particularly high-dose-rate (HDR) brachytherapy, have optimized radiation delivery, leading to shorter treatment durations and improved patient outcomes. Personalized treatment approaches, guided by genomic and molecular profiling, allow for customized dosimeter, maximizing therapeutic effectiveness while minimizing toxicity. Additionally, combining brachytherapy with other treatment modalities such as surgery, external beam radiation therapy (EBRT), and chemotherapy has demonstrated synergistic benefits, improving local control and reducing recurrence rates. Despite its advantages, brachytherapy faces challenges, including the invasive nature of the procedure, the need for specialized equipment and training, and limitations related to tumor size. Future directions in the field include advancements in imaging and dosimeter, the development of robotic-assisted brachytherapy, and more personalized treatment plans. These innovations promise to refine brachytherapy further and expand its applicability. This review highlights the transformative potential of recent advances in brachytherapy, emphasizing its evolving role in the localized treatment of oral cancers.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100654"},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024005004/pdfft?md5=de4d017ee953f597078b5dc22e05f558&pid=1-s2.0-S2772906024005004-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combining radiotherapy and systemic therapies in oropharyngeal cancer: A comprehensive review of recent developments 口咽癌放疗与全身治疗的结合：最新进展综述

Oral Oncology Reports Pub Date : 2024-09-19 DOI: 10.1016/j.oor.2024.100659

Madhan Krishnan, Shyamaladevi Babu

{"title":"Combining radiotherapy and systemic therapies in oropharyngeal cancer: A comprehensive review of recent developments","authors":"Madhan Krishnan, Shyamaladevi Babu","doi":"10.1016/j.oor.2024.100659","DOIUrl":"10.1016/j.oor.2024.100659","url":null,"abstract":"<div><div>Oropharyngeal cancer (OPC) has seen significant advancements in treatment modalities, particularly with the integration of radiotherapy and systemic therapies. This review comprehensively examines recent developments in combining these treatments, focusing on their synergistic potential, clinical outcomes, and future prospects. Advances in radiotherapy, including intensity-modulated radiotherapy (IMRT), proton beam therapy (PBT), and stereotactic body radiotherapy (SBRT), have improved targeting and reduced toxicity. Concurrent chemoradiotherapy (CCRT) remains a cornerstone, while the onset of immunotherapy, especially immune checkpoint inhibitors, has transformed systemic treatment. Combining radiotherapy with immunotherapy shows promise in enhancing treatment efficacy. Targeted therapies, such as those targeting the epidermal growth factor receptor (EGFR), are also explored for their potential in OPC management. The review underscores the importance of personalized treatment approaches and highlights ongoing research into novel therapeutic combinations and advanced technologies like artificial intelligence and machine learning. These advancements aim to optimize treatment strategies, improve survival rates, and minimize treatment-related toxicity, heralding a new era in OPC management.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100659"},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024005053/pdfft?md5=f9ee3f5b239d8f01f715ac3afe275945&pid=1-s2.0-S2772906024005053-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current advances in immunotherapy for cancer 癌症免疫疗法的最新进展

Oral Oncology Reports Pub Date : 2024-09-18 DOI: 10.1016/j.oor.2024.100652

Indrajit Desai , Saee Thakur , Pradeep Pagariya

{"title":"Current advances in immunotherapy for cancer","authors":"Indrajit Desai , Saee Thakur , Pradeep Pagariya","doi":"10.1016/j.oor.2024.100652","DOIUrl":"10.1016/j.oor.2024.100652","url":null,"abstract":"<div><div>Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance the body's immune response against tumors, offering substantial benefits in cancers like melanoma, non-small-cell lung cancer, and lymphoma. CAR-T cell therapy has demonstrated remarkable efficacy in hematologic malignancies, particularly B-cell leukemias and lymphomas, through the genetic modification of T-cells to target tumor-specific antigens.Despite these successes, several challenges remain, particularly in the treatment of solid tumors. The heterogeneity of tumor antigens, the presence of physical barriers that impede CAR-T cell infiltration, and the immunosuppressive tumor microenvironment limit the effectiveness of these therapies. To address these issues, ongoing research is exploring combination therapies that integrate ICIs with CAR-T cell therapy, improved CAR-T cell engineering, and strategies to modulate the tumor microenvironment to enhance immune cell infiltration and function.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100652"},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004989/pdfft?md5=9b7ce80b933ef99a3f68538ac720b265&pid=1-s2.0-S2772906024004989-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142314667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma 治疗口咽鳞癌的新兴免疫检查点抑制剂

Oral Oncology Reports Pub Date : 2024-09-12 DOI: 10.1016/j.oor.2024.100650

Pandiselvi Ravi , Shyamaladevi Babu

{"title":"Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma","authors":"Pandiselvi Ravi , Shyamaladevi Babu","doi":"10.1016/j.oor.2024.100650","DOIUrl":"10.1016/j.oor.2024.100650","url":null,"abstract":"<div><p>Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a challenging subtype of head and neck cancer that traditionally has been associated with poor prognosis and high morbidity due to the limitations of conventional treatments such as surgery, radiation, and chemotherapy. Immune checkpoint inhibitors have revolutionized OPSCC and other cancer therapies. ICIs that target the PD-1 and PD-L1 axis and CTLA-4 have altered cancer action by improving the immune system capacity to detect and kill cancer cells. This paper discusses the significant impact of ICIs like Pembrolizumab and Nivolumab, which have been approved for use in recurrent or metastatic OPSCC and have demonstrated remarkable efficacy in clinical trials. The integration of these therapies into clinical practice has been facilitated by the identification of biomarkers such as PD-L1 expression, which guides personalized treatment strategies. Moreover, ongoing research into combination therapies involving ICIs and other treatment modalities is poised which, leads for further improvement in patient outcomes. Despite the successes, challenges such as immune-related adverse events and resistance mechanisms remain, underscoring the need for continued innovation and exploration in the field. This review highlights the pivotal role of ICIs in redefining OPSCC treatment, offering new hope for sustained survival and improved quality of life.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100650"},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004965/pdfft?md5=1bba1c33fd8f844785a4d0d026540be8&pid=1-s2.0-S2772906024004965-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the editor, “Incidental dose to the oropharynx with involved neck only radiotherapy in squamous cell cancer of unknown primary of the head and neck.” 致编辑的信，"头颈部原发灶不明的鳞状细胞癌仅采用颈部受累放疗时口咽部的偶发剂量"。

Oral Oncology Reports Pub Date : 2024-09-10 DOI: 10.1016/j.oor.2024.100648

Gnanaprakash Jeyaraj

引用次数: 0